Health Secretary Kennedy issues enforcement-discretion policy allowing compounding of six peptides
Robert F. Kennedy, the U.S. Health Secretary, announced a policy that stops HHS from enforcing against compounding pharmacies that produce six specific peptide substances, despite FDA scientists’ safety concerns.
The U.S. Department of Health and Human Services released an "Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances" that will halt enforcement actions against specialty pharmacies that compound six peptide drugs: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. The policy, posted to the Federal Register on Wednesday with a final publication date set for October 30, does not change the regulatory status of the peptides but merely signals that HHS will not pursue violations related to their compounding.
Health Secretary Robert F. Kennedy, who has publicly said he uses some of the peptides, said the rule will curb the sale of research-use-only versions supplied by foreign manufacturers and provide a "more controlled alternative" for patients. The accompanying HHS explanation argues that broader availability through regulated compounding pharmacies will improve safety by reducing reliance on gray-market sources.
FDA scientists have warned that evidence of efficacy for the six peptides is lacking and that potential risks remain uncharacterized. In 2023, the agency removed the substances from the list of drugs that specialty pharmacies may compound because of safety concerns.
Critics, including the Center for Science in the Public Interest and Americans for Safe and Effective Medicines, contend that the policy could increase exposure to untested products and diminish incentives for formal clinical trials. Fred Mills, chief policy officer of ASEM, said the rule "does not resolve problems with untested products, safety risks, questionable ingredients, or misleading claims. In fact, we believe this will worsen what we have already seen—the harms from mass compounding hitting communities hard due to a lack of oversight to rein in bad actors."
Industry supporters celebrated the change. Brigham Buhler, who operates a wellness clinic selling peptides, thanked Kennedy, President Trump, Calley Means and Joe Rogan on social media, stating, "Medical freedom just took a major step forward!" Zachary Shurtleff, a marketing executive for a compounding pharmacy, wrote, "Peptides are BACK like they never shoulda left!" Lee Rosebush, chair of the American Academy of Peptide Medicine, issued a statement thanking Kennedy and the Trump administration for a "forward-thinking, evidence-based approach to the regulation of peptides."